evidence/gaps
Cochrane · systematic review · CD013457

The effectiveness and adverse effects of D‐cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder

Aye, SZ, Ni, H, Sein, HH, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library

Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 100%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

D‐cycloserine versus placebo for the treatment of social skills deficits in people with autism spectrum disorder

Population: children aged 5 to 11 years with ASD
6 questions
OutcomeEffectEvidenceStatus / GRADE
Social interaction impairment
D‐cycloserine vs placebo
no estimate extracted1 study · 67 participantsLow
Downgraded: risk of bias, imprecision
Social communication impairment
D‐cycloserine vs placebo
no estimate extracted1 study · 67 participantsLow
Downgraded: risk of bias, imprecision
Stereotyped patterns of behaviour and interests
D‐cycloserine vs placebo
no estimate extracted1 study · 67 participantsLow
Downgraded: risk of bias, imprecision
Total adverse events
D‐cycloserine vs placebo
RR 1.11 [0.94, 1.31]1 study · 67 participantsLow
Downgraded: risk of bias, imprecision
Non‐core symptoms of ASD
D‐cycloserine vs placebo
RR 0.97 [0.49, 1.93]1 study · 67 participantsLow
Downgraded: risk of bias, imprecision
Tolerability
D‐cycloserine vs placebo
RR 0.32 [0.01, 7.68]1 study · 67 participantsLow
Downgraded: risk of bias, imprecision